Fortress Biotech, INC. (FBIOP) — 10-Q Filings

10-Q Filings (6)

• Fortress Biotech Swings to Profit on Revenue Growth, R&D Cuts — Nov 14, 2025 Risk: medium
  Fortress Biotech, Inc. reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. For the three-mont
• Fortress Biotech Swings to Profit on Subsidiary Deconsolidation Gain — Aug 14, 2025 Risk: high
  Fortress Biotech, Inc. reported a significant turnaround in net income attributable to Fortress, reaching $15.486 million for the three months ended June 30, 20
• Fortress Biotech Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $34.3 million and total liabilities of $2.8 mil
• Fortress Biotech Q3 2024: Assets $19.7M, Liabilities $7.2M — Nov 14, 2024 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $19.7 million and total liabilities of $7.2
• Fortress Biotech Q2 2024: Assets $225.9M, Liabilities $15.1M — Aug 13, 2024 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $225.9 million and total liabilities of $15.1 mi
• Fortress Biotech, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Fortress Biotech, Inc. (FBIOP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Fortress Biotech, Inc. filed a 10-Q for the period ending March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX